Get the Stockscreener App
1.33
3.10%
0.04
Shattuck Labs Inc stock is traded at $1.33, with a volume of 17,574.
It is up +3.10% in the last 24 hours and up +15.65% over the past month.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
See More
Previous Close:
$1.29
Open:
$1.31
24h Volume:
17,574
Relative Volume:
0.08
Market Cap:
$61.58M
Revenue:
$2.72M
Net Income/Loss:
$-85.08M
P/E Ratio:
-0.6891
EPS:
-1.93
Net Cash Flow:
$-70.93M
1W Performance:
+0.00%
1M Performance:
+15.65%
6M Performance:
-61.22%
1Y Performance:
-84.90%
1-Day Range:
$1.31
$1.34
1-Week Range:
$1.21
$1.36
52-Week Range:
$0.94
$11.76
Shattuck Labs Inc Stock (STTK) Company Profile
Name
Shattuck Labs Inc
Sector
Industry
Phone
512-900-4690
Address
500 W. 5TH STREET, AUSTIN
Compare STTK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
STTK
Shattuck Labs Inc
|
1.34 | 61.58M | 2.72M | -85.08M | -70.93M | -1.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
481.00 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.64 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
648.37 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.98 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
117.05 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
Shattuck Labs Inc Stock (STTK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-02-24 | Downgrade | Citigroup | Buy → Neutral |
| Oct-02-24 | Downgrade | Needham | Buy → Hold |
| Oct-01-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Aug-31-22 | Initiated | BTIG Research | Buy |
| Jun-01-22 | Initiated | Citigroup | Buy |
| May-02-22 | Initiated | H.C. Wainwright | Buy |
| Apr-14-21 | Initiated | Berenberg | Buy |
| Jan-11-21 | Initiated | Evercore ISI | Outperform |
| Nov-03-20 | Initiated | Citigroup | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Needham | Buy |
View All
Shattuck Labs Inc Stock (STTK) Latest News
Shattuck Labs reports positive preclinical SL-325 data By Investing.com - Investing.com Nigeria
Shattuck Labs reports positive preclinical SL-325 data - Investing.com
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at the 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 - The Manila Times
Shattuck Labs Announces Positive Data from the Preclinical GLP Toxicology Study of SL-325 at ... - The Bakersfield Californian
Breakthrough in IBD Treatment? Shattuck's Novel DR3 Blocker Achieves Perfect Safety Score - StockTitan
Shattuck Labs (STTK) Expected to Announce Earnings on Wednesday - Defense World
Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 - The Manila Times
GoHealth to Announce Fourth Quarter 2024 Results on February 27, 2025 - The Manila Times
Revolutionary IBD Drug Development: Shattuck Labs Unveils Critical DR3 Antibody Results at ECCO 2025 - StockTitan
Shattuck Labs Reports Second Quarter 2024 Financial Results and Recent Business Highlights - br.ADVFN.com
Anti-DR3 antibody demonstrates efficacy in the treatment of IBD - BioWorld Online
Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress - The Manila Times
Skye Bioscience Announces Participation in February Conferences - The Manila Times
Shattuck Labs, Inc. to Present Novel Research on SL-325 at 2025 Crohn’s and Colitis Congress - Nasdaq
Pivotal IBD Drug Development: Shattuck Labs Reveals SL-325 Data at Major Crohn's Congress - StockTitan
JPMorgan Chase & Co. Grows Position in Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
Planet Image International Leads 3 US Penny Stocks To Consider - Simply Wall St
Cresco Labs (OTCMKTS:CRLBF) Trading 2.1% Higher – What’s Next? - Defense World
ImmunoMet Therapeutics Presents Updated Clinical Data from Phase 1b Study of Lixumistat in Pancreatic Cancer at ASCO-GI Meeting - BioSpace
Can ALX Break The CD47 Curse? - News & Insights
AXA (EPA:CS) Stock Price Crosses Above 200 Day Moving Average – Here’s Why - Defense World
Barclays PLC Has $189,000 Stock Holdings in Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Stabilus (OTCMKTS:SBLUY) Stock Price Up 10.9% – Still a Buy? - Defense World
Shattuck Labs, Inc. (NASDAQ:STTK) Shares Sold by Jane Street Group LLC - Defense World
Luna Innovations Incorporated (NASDAQ:LUNA) Shares Sold by Jane Street Group LLC - Defense World
Jane Street Group LLC Boosts Stock Holdings in System1, Inc. (NYSE:SST) - Defense World
Barclays PLC Buys 40,717 Shares of Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
Geode Capital Management LLC Raises Position in Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
Shattuck Labs CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Shattuck Labs highlights upcoming key milestones in 2025 - Yahoo Finance
Shattuck Labs gears up for DR3 antagonist trials in 2025 By Investing.com - Investing.com Australia
Shattuck Labs gears up for DR3 antagonist trials in 2025 - Investing.com
Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 - The Manila Times
Shattuck Labs Unveils 2025 Pipeline Roadmap: Key SL-325 Clinical Milestones, $90M Cash Position - StockTitan
State Street Corp Acquires 55,579 Shares of Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
Barfresh Food Group And 2 Other US Penny Stocks To Consider - Simply Wall St
STTK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Shattuck Labs, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online
MetLife Investment Management LLC Raises Holdings in Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
STTK LAWSUIT ALERT: Levi & Korsinsky Notifies Shattuck Labs, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Marketscreener.com
Shattuck Labs, Inc. (NASDAQ:STTK) Director Buys $166,713.75 in Stock - MarketBeat
Redmile Group, LLC Reduces Stake in Shattuck Labs Inc - GuruFocus.com
Shattuck Labs sees $166,713 in stock sales by Redmile Group - Investing.com
New VC fund from hedge fund luminary seeks to raise $100M, filing shows - The Business Journals
GSA Capital Partners LLP Invests $121,000 in Shattuck Labs, Inc. (NASDAQ:STTK) - Defense World
Shattuck Labs to Present at Piper Sandler and Evercore Healthcare Conferences | STTK Stock News - StockTitan
Shattuck Labs Falls To US$1.01, But Insiders Sold At Lower Price - Simply Wall St
Shattuck Labs stock plunges to 52-week low at $1.06 By Investing.com - Investing.com Canada
Shattuck Labs stock plunges to 52-week low at $1.06 - Investing.com India
Citigroup Downgrades Shattuck Labs (STTK) - MSN
Shattuck Labs’ (STTK) Neutral Rating Reaffirmed at HC Wainwright - Defense World
Shattuck Labs Inc Stock (STTK) Financials Data
Revenue
Net Income
Cash Flow
EPS
Shattuck Labs Inc Stock (STTK) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | Director |
Dec 04 '24 |
Sale |
1.25 |
133,371 |
166,714 |
5,406,353 |
0.42%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):